1
|
Xie J, Ekpo MD, Xiao J, Zhao H, Bai X, Liang Y, Zhao G, Liu D, Tan S. Principles and Protocols For Post-Cryopreservation Quality Evaluation of Stem Cells in Novel Biomedicine. Front Pharmacol 2022; 13:907943. [PMID: 35592426 PMCID: PMC9113563 DOI: 10.3389/fphar.2022.907943] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 04/13/2022] [Indexed: 01/05/2023] Open
Abstract
Stem cell therapy is a thriving topic of interest among researchers and clinicians due to evidence of its effectiveness and promising therapeutic advantage in numerous disease conditions as presented by novel biomedical research. However, extensive clinical application of stem cells is limited by its storage and transportation. The emergence of cryopreservation technology has made it possible for living organs, tissues, cells and even living organisms to survive for a long time at deep low temperatures. During the cryopreservation process, stem cell preparations are subject to three major damages: osmotic damage, mechanical damage, and peroxidative damage. Therefore, Assessing the effectiveness and safety of stem cells following cryopreservation is fundamental to the quality control of stem cell preparations. This article presents the important biosafety and quality control parameters to be assessed during the manufacturing of clinical grade stem cell products, highlights the significance of preventing cryodamage. and provides a reference for protocols in the quality control of stem cell preparations.
Collapse
Affiliation(s)
- Jingxian Xie
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.,Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| | - Marlene Davis Ekpo
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| | - Jian Xiao
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
| | - Hongbin Zhao
- Hunan Carnation Biotechnology Co. LTD, Changsha, China.,Hainan Nova Doctor Group Co. Ltd, Haikou, China
| | - Xiaoyong Bai
- Hunan Carnation Biotechnology Co. LTD, Changsha, China.,Hainan Nova Doctor Group Co. Ltd, Haikou, China
| | - Yijie Liang
- Hunan Carnation Biotechnology Co. LTD, Changsha, China.,Hainan Nova Doctor Group Co. Ltd, Haikou, China
| | - Guang Zhao
- Hunan Sheng Bao Biological Technology Co., Ltd (in Yinfeng Biological Group., Ltd), Changsha, China
| | - Dong Liu
- Hunan Sheng Bao Biological Technology Co., Ltd (in Yinfeng Biological Group., Ltd), Changsha, China
| | - Songwen Tan
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| |
Collapse
|